This upregulation and reprogramming of glucose metabolism induced by LIF overexpression were observed in different subtypes of breast cancers, including luminal A, basal-like, Her2+, and TNBC cancers, in both in vitro cultured cells and in vivo xenograft tumor models. This evidence concerns the gene ERBB2 and breast carcinoma.